首页> 外文期刊>Trials >Hepatitis C – Assessment to Treatment Trial (HepCATT) in primary care: study protocol for a cluster randomised controlled trial
【24h】

Hepatitis C – Assessment to Treatment Trial (HepCATT) in primary care: study protocol for a cluster randomised controlled trial

机译:丙型肝炎–初级保健治疗试验评估(HepCATT):一项整群随机对照试验的研究方案

获取原文
           

摘要

Background Public Health England (PHE) estimates that there are upwards of 160,000 individuals in England and Wales with chronic hepatitis C virus (HCV) infection, but until now only around 100,000 laboratory diagnoses have been reported to PHE and of these 28,000 have been treated. Targeted case-finding in primary care is estimated to be cost-effective; however, there has been no robust randomised controlled trial evidence available of specific interventions. Therefore, this study aims to develop and conduct a complex intervention within primary care and to evaluate this approach using a cluster randomised controlled trial. Methods/design A total of 46 general practices in South West England will be randomised in a 1:1 ratio to receive either a complex intervention comprising: educational training on HCV for the practice; poster and leaflet display in the practice waiting rooms to raise awareness and encourage opportunistic testing; a HCV risk prediction algorithm based on information on possible risk markers in the electronic patient record run using Audit?+?software (BMJ Informatica). The audit will then be used to recall and offer patients a HCV test. Control practices will follow usual care. The effectiveness of the intervention will be measured by comparing number and rates of HCV testing, the number and proportion of patients testing positive, onward referral, rates of specialist assessment and treatment in control and intervention practices. Intervention costs and health service utilisation will be recorded to estimate the NHS cost per new HCV diagnosis and new HCV patient initiating treatment. Longer-term cost-effectiveness of the intervention in improving quality-adjusted life years (QALYs) will be extrapolated using a pre-existing dynamic health economic model. Patients’ and health care workers’ experiences and acceptability of the intervention will be explored through semi-structured qualitative interviews. Discussion This trial has the potential to make an important impact on patient care and will provide high-quality evidence to help general practitioners make important decisions on HCV testing and onward referral. If found to be effective and cost-effective the intervention is readily scalable and can be used to support the implementation of NICE recommendations on HCV case-finding. Trial registration ISRCTN61788850 . Registered on 24 April 2015; Protocol Version: 2.0, 22 May 2015.
机译:背景英格兰公共卫生(PHE)估计,英格兰和威尔士有超过160,000个人患有慢性丙型肝炎病毒(HCV)感染,但迄今为止,据报道,PHE仅接受了约100,000例实验室诊断,其中28,000例已得到治疗。估计在初级保健中有针对性的病例发现具有成本效益;但是,尚无针对特定干预措施的可靠的随机对照试验证据。因此,本研究旨在开发和进行初级保健中的复杂干预措施,并使用整群随机对照试验评估这种方法。方法/设计将以1:1的比例将英格兰西南部地区的总共46种常规做法随机分配,以接受以下复杂干预措施:在练习候诊室张贴海报和传单,以提高认识并鼓励进行机会试验;一种基于HCV风险预测算法的算法,该算法基于使用Audit?+?软件(BMJ Informatica)运行的电子病历中可能的风险标记信息。然后,审核将用于召回并为患者提供HCV测试。控制措施将遵循常规护理。干预措施的有效性将通过比较HCV检测的数量和比率,检测为阳性,继续转诊的患者的数目和比例,对照和干预措施中专家评估和治疗的比率来衡量。将记录干预费用和卫生服务利用情况,以估算每次新的HCV诊断和新的HCV患者开始治疗所需的NHS费用。使用已有的动态卫生经济模型可以推断出干预措施在改善质量调整生命年(QALYs)中的长期成本效益。将通过半结构化的定性访谈来探讨患者和医护人员的经验以及干预的可接受性。讨论该试验有可能对患者的护理产生重要影响,并将提供高质量的证据来帮助全科医生就HCV检测和继续转诊做出重要决定。如果发现有效且具有成本效益,则该干预措施可以轻松扩展,并可用于支持执行NICE关于HCV病例发现的建议。试用注册ISRCTN61788850。 2015年4月24日注册;协议版本:2.0,2015年5月22日。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号